TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04010968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venetoclax and ibrutinib (I+VEN)
Description: The treatment will start with ibrutinib alone for 3 months (lead-in phase) from Month 1 to Month 3 and then venetoclax will be added from Month 4 with an initial ramp-up period.~The total duration of treatment with (I+VEN) will depend on the response achieved at Month 9:~* if BM MRD at M9 \< 0.01%, the treatment with (I+VEN) will be continued for 6 additional months until Month 15 and stopped then. MRD will be assessed at Month 15 (PB), Month 21 (PB) and Month 27 (PB and BM)~* if BM MRD at M9 ≥ 0.01%, the treatment with (I+VEN) will be continued for 18 additional months until Month 27 and stopped then, whatever the results of MRD assessments that will be performed at the same time points as above.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FCR
Description: All patients will receive 6 cycles of FCR administered at 4 weeks intervals (D1 = D29) from Month 1 to Month 6.~6 cycles of FCR will be administered at 4 weeks intervals (D1 = D29) from Month 1 to Month 6.
Study: NCT03918980

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules will be administered in parts 1,2, 4 and 6.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules will be administered in parts 1,2, 4 and 6.
Study: NCT01470352

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Doluxetine
Description: 30 mg/d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doluxetine
Description: 30 mg/d

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: suger pill 30mg/d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: suger pill 30mg/d
Study: NCT00364416

Intervention type: OTHER
Intervention: Any treatment used to treat CHF
Description: Clinical Outcomes of Chronic Decompensated Heart Failure patients
Study: NCT02866409

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: scalp block
Description: In this group following nerves were blocked-~1. Supra-orbital nerve~2. Supra-trochlear nerve~3. Zygomatico-temporal nerve~4. Auriculo-temporal nerve~5. Posterior auricular branches of the greater auricular Nerve~6. The greater, lesser, and third occipital nerves

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: infiltration
Description: The incision site was infiltrated with drug. {1/3rd in the muscle and 2/3rd in the subcutaneous tissue}.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: infiltration
Description: The incision site was infiltrated with drug. {1/3rd in the muscle and 2/3rd in the subcutaneous tissue}.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine was administered as a dose of 1 µg/kg in 20 ml 0.25% bupivacaine for scalp block or infiltration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine was administered as a dose of 1 µg/kg in 20 ml 0.25% bupivacaine for scalp block or infiltration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 20 ml of Bupivacaine 0.25% was administered to the patients either in the form of scalp block or infiltration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 20 ml of Bupivacaine 0.25% was administered to the patients either in the form of scalp block or infiltration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 20 ml of Bupivacaine 0.25% was administered to the patients either in the form of scalp block or infiltration
Study: NCT00863239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: Co-administered in all arms: oral ribavirin, 200 mg capsules. Subjects with body weight \< 65 kg: 800 mg/day; Subjects with body weight 65-85 kg: 1000 mg/day; Subjects with body weight \> 85 kg: 1200 mg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: Co-administered in all arms: oral ribavirin, 200 mg capsules. Subjects with body weight \< 65 kg: 800 mg/day; Subjects with body weight 65-85 kg: 1000 mg/day; Subjects with body weight \> 85 kg: 1200 mg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: Co-administered in all arms: oral ribavirin, 200 mg capsules. Subjects with body weight \< 65 kg: 800 mg/day; Subjects with body weight 65-85 kg: 1000 mg/day; Subjects with body weight \> 85 kg: 1200 mg/day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ribavirin
Description: Co-administered in all arms: oral ribavirin, 200 mg capsules. Subjects with body weight \< 65 kg: 800 mg/day; Subjects with body weight 65-85 kg: 1000 mg/day; Subjects with body weight \> 85 kg: 1200 mg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Locteron™ (controlled-release interferon alpha 2b)
Description: investigational controlled-release recombinant interferon alpha 2b formulated in 1500/77/23 PolyActive microspheres as a lyophilized powder, reconstituted with carboxymethyl cellulose immediately before subcutaneous injection every other week as part of the treatment of chronic hepatitis C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Locteron™ (controlled-release interferon alpha 2b)
Description: investigational controlled-release recombinant interferon alpha 2b formulated in 1500/77/23 PolyActive microspheres as a lyophilized powder, reconstituted with carboxymethyl cellulose immediately before subcutaneous injection every other week as part of the treatment of chronic hepatitis C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Locteron™ (controlled-release interferon alpha 2b)
Description: investigational controlled-release recombinant interferon alpha 2b formulated in 1500/77/23 PolyActive microspheres as a lyophilized powder, reconstituted with carboxymethyl cellulose immediately before subcutaneous injection every other week as part of the treatment of chronic hepatitis C

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG-Intron™
Description: commercially available pegylated interferon alpha 2b injected subcutaneously weekly in a dose of 1.5 ug/kg as part of the treatment of chronic hepatitis C
Study: NCT01501071

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esophageal calibration tube
Description: An orogastric calibration tube is inserted during laparoscopic Nissen fundoplication in order to secure a certain esophageal lumen for reducing postoperative dysphagia
Study: NCT01785472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Description: LCZ696 200 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Description: LCZ696 200 mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olmesartan
Description: Olmesartan 20 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of LCZ696
Description: Placebo tablet of LCZ696 200 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of LCZ696
Description: Placebo tablet of LCZ696 200 mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of LCZ696
Description: Placebo tablet of LCZ696 200 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of Olmesartan
Description: Placebo capsule of olmesartan 20 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of Olmesartan
Description: Placebo capsule of olmesartan 20 mg once daily
Study: NCT03250663

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Treatment response
Description: Electronic treatment response survey to track use of study medication, EUCRISA (crisaborole) ointment 2%.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EUCRISA
Description: Participants are given EUCRISA (crisaborole) ointment 2%.
Study: NCT01898624

Intervention type: DRUG
Intervention: mirabegron
Description: oral
Study: NCT03348319

Intervention type: OTHER
Intervention: radiation
Description: Scanning cadaver organs
Study: NCT03325062

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The contemporary progressive rehabilitation program consists of progressive resistive exercise to key lower extremity muscle groups, knee range of motion exercise, weight-bearing exercise, as well as education on symptom management strategies.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: MOVE
Description: The MOVE program emphasizes movement pattern retraining in conjunction with contemporary rehabilitation. More specifically, the MOVE program promotes symmetry in functional knee motion and loading without postural compensation. Intervention uses pressure-sensing shoe insoles to deliver real-time visual biofeedback during activity performance.
Study: NCT03250663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EUCRISA
Description: Participants are given EUCRISA (crisaborole) ointment 2%.
Study: NCT00417560

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: inactivated influenza A/H5N1 vaccine
Study: NCT03806452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxycarbamide
Description: Hydroxycarbamide tablets of 100 and 1000 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo tablets of 100 and 1000 mg to mimic hydroxycarbamide tablets
Study: NCT02176733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Study: NCT04151810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDP1
Description: Single dose part:~Cohort 1:400 mg/m2; Cohort 2: 500 mg/m2; Cohort 3: 750 mg/m2;~Multi-dose Part:~Starting dose: Cohort 1:400 mg/m2; Cohort 2/3: 500 mg/m2; Maintenance dose: Cohort 1:250 mg/m2, QW; Cohort 2/3: 500 mg/m2, Q2W;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDP1
Description: Starting dose: 400 mg/m2; Maintenance dose: 250 mg/m2,QW;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIP chemotherapy
Description: Paclitaxel: 175 mg/m2 in day 1, Q3W; Ifosfamide: 1200 mg/m2 in day 1, day 2 and day 3, Q3W; Cisplatin: 25 mg/m2 in day 1, day 2 and day 3, Q3W; Participants received TIP chemotherapy up to 6 cycles (21 days per cycle).
Study: NCT03858075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLU-782
Description: oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLU-782
Description: oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLU-782
Description: oral capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLU-782 taken with food
Description: oral capsules
Study: NCT00618215

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: peer group educational implementation strategy
Description: Delivery CPG~Education session IQual group~Online training website (individual feed back)~Reminder (flow chart), individual feed back record form~Feed back by email~Registration in practice

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: peer group educational implementation strategy
Description: Delivery CPG~Education session IQual group~Online training website (individual feed back)~Reminder (flow chart), individual feed back record form~Feed back by email~Registration in practice
Study: NCT00375193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amrubicin
Description: Amrubicin 40mg/m\<2\> IV days 1, 2, 3 of each 21-day cycle until Cycle 6 or no longer beneficial
Study: NCT02618993

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Realization of the V3 block in maxillofacial surgeries
Description: bilateral mandibular block in maxillofacial surgeries

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Realization of the V3 block in maxillofacial surgeries
Description: bilateral mandibular block in maxillofacial surgeries
Study: NCT01006811

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: modified Atkins diet
Description: Modified Atkins Diet administration~1. Carbohydrates intake restricted to 10 grams/ day. (Carbohydrate values of various food items will be explained in detail, and exchange lists provided. Four 2.5 grams carbohydrate exchange items will be allowed in a day.)~2. Fats (e.g. cream, butter, oils, ghee) encouraged.~3. Proteins (cheese, fish, eggs, chicken, soya products) unrestricted.~4. Clear carbohydrate-fluids not restricted.~5. Calcium and multivitamin supplementation will be provided.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: modified Atkins diet
Description: Modified Atkins Diet administration~1. Carbohydrates intake restricted to 10 grams/ day. (Carbohydrate values of various food items will be explained in detail, and exchange lists provided. Four 2.5 grams carbohydrate exchange items will be allowed in a day.)~2. Fats (e.g. cream, butter, oils, ghee) encouraged.~3. Proteins (cheese, fish, eggs, chicken, soya products) unrestricted.~4. Clear carbohydrate-fluids not restricted.~5. Calcium and multivitamin supplementation will be provided.
Study: NCT01260987

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional photodynamic therapy
Description: Photodynamic therapy using methyl-aminolevulinate and red light (37 J/cm2)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional photodynamic therapy
Description: Photodynamic therapy using methyl-aminolevulinate and red light (37 J/cm2)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fractional CO2 laser assisted PDT
Description: Pretreatment with fractional CO2 laser before methyl-aminolevulinate PDT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fractional CO2 laser assisted PDT
Description: Pretreatment with fractional CO2 laser before methyl-aminolevulinate PDT
Study: NCT03501797

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Singing-based rehabilitation
Description: The singing-based rehabilitation is a combination of group-training (16 weeks, 1 x week, 90 min), which utilizes a novel combination of traditional senior choir singing and singing-based speech training protocols, and home training (16 weeks, ≥ 3 x week, ≥ 30 min) in which the choir material is trained with a tablet computer.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Singing-based rehabilitation
Description: The singing-based rehabilitation is a combination of group-training (16 weeks, 1 x week, 90 min), which utilizes a novel combination of traditional senior choir singing and singing-based speech training protocols, and home training (16 weeks, ≥ 3 x week, ≥ 30 min) in which the choir material is trained with a tablet computer.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care
Description: Standard care comprises all rehabilitation and care services (e.g. speech therapy, physical and occupational therapy, neuropsychological rehabilitation) received by the patients in the Finnish health care system

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care
Description: Standard care comprises all rehabilitation and care services (e.g. speech therapy, physical and occupational therapy, neuropsychological rehabilitation) received by the patients in the Finnish health care system
Study: NCT00726115

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SAM-531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Study: NCT02137200

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate pushing
Description: Women in this arm will be instructed to initiate pushing as soon as complete cervical dilation is documented.
Study: NCT02178878

Intervention type: GENETIC
Intervention: Progress, Pain
Description: Progress, Pain
Study: NCT02137200

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Delayed pushing
Description: Women assigned to delayed pushing will be instructed to wait for 60 minutes from complete cervical dilation before pushing. Women will be allowed to push earlier if they feel an irresistible urge to push, the fetal head is visible at the perineum, or the fetal heart tracing is non-reassuring.
Study: NCT02220010

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pancreatic stent
Description: The plastic stent is introduced in the pancreatic duct by a duodenoscope
Study: NCT01141296

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fenofibrate
Description: fenofibrate 200 mg PO daily for 1 year

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo pill identical to active drug will be given PO once a day for 1 year
Study: NCT01623440

Intervention type: COMBINATION_PRODUCT
Intervention: Placebo and fMRI
Description: Pill form, participant dosed one time an hour before fMRI.

Intervention type: COMBINATION_PRODUCT
Intervention: Naltrexone and fMRI
Description: 50 mg pill given one time, one hour before fMRI
Study: NCT00058331

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: epoetin alfa

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: epoetin alfa
Study: NCT00096941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Pertuzumab was supplied as a single-use liquid formulation.
Study: NCT02070159

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel 600 mg
Description: Patients administer 600 mg of clopidogrel as conventional loading dose of clopidogrel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel 30 mg
Description: Patients administer 30 mg of prasugrel as lower loading dose of prasugrel.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel 60 mg
Description: Patients take 60 mg of prasugrel as conventional loading dose of prasugrel.
Study: NCT02304237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone
Description: micronized progesterone 200mg/day till 36 weeks 6 days of gestation or premature rupture of membranes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intramuscular progesterone
Description: hydroxyprogesterone caproate 250mg/ml/week till 36 weeks 6 days of gestation or premature rupture of membranes
Study: NCT02648087

Intervention type: DEVICE
Group type: OTHER
Intervention: With and without SDB
Description: Screening of sleep-disordered breathing (SDB)
Study: NCT01950143

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard broccoli soup
Description: Volunteers will be required to consume one portion of broccoli soup per week as part of their normal diet for one year.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beneforte broccoli soup
Description: Volunteers will be required to consume one portion per week of a soup containing glucoraphanin-enriched broccoli (Beneforte®) as part of their normal diet for one year.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beneforte extra broccoli soup
Description: Volunteers will be in which they will be required to consume one portion per week of a soup containing an other variety of glucoraphanin-enriched broccoli (Beneforte extra) as part of their normal diet for one year.
Study: NCT04436094

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Orthodontic extrusion
Description: An orthodontic attachment will be bonded to the core of the experimental tooth. Orthodontic brackets American Orthodontics Roth prescription. 0.022 slot will be bonded to the adjacent teeth. A passive rectangular stainless steel wire (0.016X0.022) will be inserted in the adjacent teeth with a step down and a coil at the site of the experimental tooth.~Orthodontic extrusion will start using a light overlay wire of 0.012 NiTi and then continued by elastic chains/ threads extending between the attachment on the tooth and the stabilizing wire. The patient is followed up for appliance activation every 3-4 weeks and extrusion is performed until an adequate ferrule effect of 2 mm is present all around the tooth circumference (in addition to the biologic width). So the extrusion is completed when the tooth is 4-4.5 mm from the alveolar bone crest as judged by periapical radiographs.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate implant placement
Description: The patient is anaesthetized. Atraumatic extraction of the badly broken down teeth will be performed using peroiotome. Luxation should be done mesiodistally and not buccolingually, to avoid damaging the buccal plate. After tooth removal, a curette is used to confirm that the location of the buccal plate is intact. Standard drilling procedures are performed according to the manufacturer's instructions. Then the implant is placed in the prepared site. Temporization should be done using composite 3M Filtek Z250 XT material. Finally, a porcelain fused to zirconia crown will be performed.
Study: NCT03121664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF06649751, Itraconazole
Description: PF-06649751 0.25 mg on Days 1,2,3 PF-06649751 0.5 mg on Days 4,5,6 PF-06649751 1 mg on Days 7 to Day 25 Itracoanzole 200 mg on Days 12 to Day 25
Study: NCT01336465

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Repeating subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhuMAb Beta7
Description: Repeating subcutaneous injection
Study: NCT03050086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPX-04 1% minocycline topical gel
Description: once daily administration of topical minocycline gel to face

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPX-04 2% minocycline topical gel
Description: once daily administration of topical minocycline gel to face

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BPX-04 vehicle topical gel
Description: once daily administration of topical minocycline gel to face
Study: NCT01166984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB103
Description: Single intravenous infusion at doses of 7.5 µg/kg, 37.5 µg/kg, 150 µg/kg, or 450 µg/kg administered over approximately 10 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB103
Description: Single intravenous infusion at doses of 7.5 µg/kg, 37.5 µg/kg, 150 µg/kg, or 450 µg/kg administered over approximately 10 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB103
Description: Single intravenous infusion at doses of 7.5 µg/kg, 37.5 µg/kg, 150 µg/kg, or 450 µg/kg administered over approximately 10 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB103
Description: Single intravenous infusion at doses of 7.5 µg/kg, 37.5 µg/kg, 150 µg/kg, or 450 µg/kg administered over approximately 10 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single intravenous infusion of normal saline (0.9% sodium chloride) administered over approximately 10 minutes
Study: NCT01298284

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propranolol
Description: Starting from 20 mg daily, titrated weekly to decrease heart rate more than 25 % of baseline, administrated during the whole study period